Abstract 2320
Background
Breast cancer (BC) is the most frequent cancer in women. About 15% of all cases account for the most aggressive subtype: triple negative breast cancer (TNBC). TNBC biological heterogeneity has been explained in both gene expression profile studies and genome wide association studies (GWAS). Our study explores the role of single nucleotide polymorphisms (SNP) in TNBC. We hypothesized that new loci can confer risk and prognosis of TNBC, given its well-known tendency to genetic aberrations.
Methods
In this retrospective study, we genotyped a group of SNP in 111 paraffin-embedded tumor samples of patients diagnosed with TNBC (cases) and in 176 blood samples of healthy donors (controls). The SNP were selected from 5 genes (MAP3K1, PI3K, TERT, EGFR, and mTOR) known for their implication in TNBC and other types of cancer.
Results
Univariate analysis with chi-square test comparing genotypic frequencies between cases and controls confirmed statistical significance in EGFR rs4947986 (p= 0.001) and TERT rs2736100 (p=
Conclusions
Our study found no prognostic significance of SNP for disease free survival (DFS) or overall survival (OS) in the multivariate analyses including TNM stage, axillary status, treatment (chemotherapy and/or radiotherapy) and age.
Our findings not only confirm the genetic influence of molecular pathways in EGFR, PI3K, mTOR and MAP3K1 but also reveal new loci for development of TNBC.
Having recognized new TERT and EGFR mutations in our cohort encourages us to keep unveiling plausible new pathways on carcinogenesis and treatment targets for TNBC. However, more translational studies are mandatory.
Clinical trial identification
Legal entity responsible for the study
Hospital Universitari Mutua Terrassa-Oncology and Hematology Department
Funding
Hospital Universitari Mutua Terrassa
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract